ArticleCancer medicine2024

Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.

Doris K Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.